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Older adults generally have more unfavorable prognostic factors at presentation and their treatment is made more difficult by their inability to withstand the intensity of chemotherapy. Further, the type of post-remission therapy that they receive is generally considered sub-optimal even for the less poor prognostic groups seen in younger adults. In essence, that is the crux of the problem; a biologically unfavorable disease that gets treated sub-optimally ( Table 1) .
The long-term prognosis is indeed dismal. A recent update by the Eastern Cooperative Oncology Group (ECOG) reviewed the long-term survival of 2882 patients treated between 1973 and 1996. All patients who entered these studies are included regardless whether or not they completed protocol therapy. The median survival for all 2882 patients was 11 months (Figure 1 ). However, for patients older than 55 years the median survival (944 patients) was 6 months with a 5-year survival of only 7.6% ( Figure 2 ).
Published data from other groups show similar dismal longterm outcome. A recent update of the EORTC-HOVON data for AML patients over 60 years reported a median survival of 9 months and a 5-year survival of 8%. 2 Data from the Fourth International Workshop on Chromosomes in Leukemia reported a 5-year survival for patients over 60 of less than 5% 3   Table 1 AML in older adults -clinical and biologic features that distinguish this from the more characteristic AML seen in younger adults and a recent update from the Cancer and Leukemia Group B (CALGB) of almost 400 older patients treated intensively on consecutive protocols reported a 5-year survival of only 5%. 4 Of interest, the published data are probably overly optimistic and misleading. As early as 1982, data published from the University of Chicago demonstrated that the incidence of specific translocations is highest in younger adults whereas the incidence of more unfavorable cytogentics, such as deletions of whole or part of chromosomes 5 or 7, as well as complex karyotypes, are more common in older adults. 5 Yet, the reported data from cooperative group studies do not always reflect this. The leaders of rigorous cytogenetic monitoring and central review have been the CALGB, and if one observes their published data (Table 2), the incidence of unfavorable cytogenetics, surprisingly, is not significantly higher in older adults suggesting, perhaps, that many patients with unfavorable cytogenetics are not even entered on standard protocols even though there are no data that anything else is superior. Thus, it seems that the published data are probably not representative of community practice, partly because the degree of patient selection is usually not described and, in any event, older patients referred to leukemia treatment centers are already a pre-selected group.
Intrinsic prognostic factors among older adults
Some superb analyses by the Southwestern Oncology Group (SWOG) reported a very high frequency of intrinsic multi-drug resistance (MDR1) among AML patients over 55 even among those considered as classically de novo. 8 Specifically, the MDR1 was expressed in more than 70% of the patients. This was highly predictable of complete remission; that is a negative prediction. Those who had high MDR1 expression were less likely to go into complete remission, and the presence of MDR1 expression was also very significantly associated with resistant disease. In contrast, MDR1 was expressed in only 30% of AML patients younger than 55 years.
One of the hallmarks of secondary leukemias is the fact that they arise in a setting of trilineage dysplasia; 9 a morphologic finding that is associated with more resistant disease. 10 A close examination of patients in SWOG also described the occurrence of trilineage dysplasia in 64% of patients over 55 with apparent de novo AML. 11 Finally, among the so-called de novo AML in older patients there is a striking preponderance of intermediate or unfavorable karyotypic abnormalities -most important being deletions of chromosome 7 or 5 as well as other monosomies, trisomies and complex karyotypes. These typical morphologic, immunophenotypic and genetic profiles among older adults are common among patients presenting with myelodysplasia (MDS) or AML that follows myelodysplasia or therapyrelated AML. In other words, the prognostic factors of AML in older adults make it often indistinguishable from classic secondary leukemia.
Older adults are unable to withstand the intensity of therapy
Figure 1
Long-term survival of patients treated on consecutive protocols of the Eastern Cooperative Oncology Group (ECOG) between 1973 and 1996. All patients that entered these studies were included in this analysis. The only exception are patients from a recent intergroup trial of APL (E2491).
Figure 2
Long-term survival data of same patients but broken-down by age -greater or less than 55 years. 4 that is usually administered to younger adults and thus receive inadequate post-remission therapy. As an example of this problem, the CALGB (Table 3) reported that among almost 400 patients, even though half the patients responded, the long-term survival at 5 years was only 5%. 4 Thus, although an increasing number of patients can achieve a good initial response, most relapse and the real challenge may be to maintain a response once this is achieved. The problem is somewhat analogous to Ph-positive ALL where although most patients can achieve a complete remission, with standard therapy virtually everyone relapses.
Therapeutic modulation: is there real progress?
Attempts to improve the therapy of older adults focuses on developments in induction, post-remission therapy, maintenance therapy, immunotherapy, MDR modulation and supportive care (Table 4) .
Is there a best induction regimen?
The short answer is that this is probably not known, but certain things are clear. While most regimens include an anthracycline and cytosine arabinoside, the optimal anthracycline and dose has not been established. There have been three convincing trials in younger adults showing that idarubicin is better than 45 mg/m 2 of daunorubicin. [12] [13] [14] Similar results have also been shown using other anthracyclines such as amsacrine, 15 mitoxantrone 16 or aclacinomycin A. 17 In other words, probably any anthracycline is better than 45 mg/m 2 of daunorubicin. What is not known is whether this represents a true biologic advantage or is merely a question of dose equivalence. At the same time the data in older adults -even for 45 mg/m 2 of daunorubicin -are equivocal and do not confirm this superiority. 18, 19 A recently completed trial by the Eastern Cooperative Oncology Group prospectively compared three induction 2 -all given intravenously for 3 daystogether with an identical dose of cytosine arabinoside, 100 mg/m 2 for 7 days, as well as an identical consolidation regimen. In this prospective trial among older adults there was no difference in efficacy between the three anthracyclines and no statistically significant difference in toxicity, although there may have been a trend for a lower therapy-related mortality using mitoxantrone. 20 It should thus be noted that for those patients not on any specific study there are very few data that justify the continued use of 45 mg/m 2 of daunorubicin as standard induction therapy. On the other hand, although there has never been a prospective comparison between 45 mg/m 2 and 60 or 70 mg/m 2 of daunorubicin, sequential studies from both SWOG and ECOG very strongly suggest that a dose of 60-70 mg/m 2 is both safe and more efficacious than 45 mg/m 2 . 21, 22 These data also do not suggest that a higher dose of daunorubicin is more toxic in older adults. 21 
Is intensive post-remission therapy appropriate in older adults?
Over the past two decades there has been some debate whether older adults should indeed receive intensive induction therapy rather than an attenuated form of therapy, or, no therapy at all.
The studies are small and limited, often not prospectively randomized. Nevertheless, they provide important information. A European study published in 1989 23 described older patients (median age 71) who were randomized to receive standard therapy at diagnosis vs those who followed a 'wait and see' approach whereby chemotherapy was only given when there was a clinical deterioration. The overall response rate was dramatically different -58% complete remission rate for those patients receiving standard therapy at diagnosis vs 0% for those only treated upon deterioration. The overall survival was similarly better.
Another study in older adults (median age 71) compared 24 standard induction therapy vs low-dose cytarabine at presentation and demonstrated a better complete response rate for patients receiving standard therapy (52% vs 32%).
The overall data on the use of low-dose cytarabine were summarized in 1986. 25 A detailed retrospective analysis of 751 patients demonstrated an unimpressive overall response rate. It should also be noted that when the low-dose cytarabine has been given with an intent to achieve a complete remission -using a 15-to 21-day course -such therapy is severely myelosuppressive with a long nadir. Thus, the preponderance of the data do not support the routine use of lowdose cytarabine, or other similar form of therapy, for remission induction in older adults who are biologically fit (Table 5) .
How much post-remission therapy can be safely given?
It has become almost uniformly accepted that high-dose cytarabine is essential for post-remission therapy especially if bone marrow transplantation is not used. Perhaps this is so, but it is important to recall the data from the MRC trial -the largest published randomized study of adult AML -which shows a disease-free survival of 40% using chemotherapy alone. 26 Even if children are excluded from this analysis, the diseasefree survival is still 38%. Although these data are presented somewhat differently, they are still as good as anything else that has been published by anyone and importantly do not include what is typically considered as high-dose cytarabine (the highest dose used was 1 g/m 2 in only one of the consolidation courses). Thus, while there is no question that highdose cytarabine is an effective post-remission therapy, 27 it is not clear if one needs to subscribe to a dogma that it is a critical element of post-remission therapy.
As for safety, data now exist on over 300 older adults who have received 12 doses of 1.5 g/m 2 of cytarabine as consolidation therapy in ECOG trials (only six doses for patients over 70). Such post-remission doses of cytarabine are very well tolerated and with a mortality rate of only 2%. 21 Furthermore, using such a consolidation course in older adults the median survival at 2 years is over 30%. Thus, the time may have come to critically evaluate and ask the question of whether a dose of 3 g/m 2 , which is often administered and is far more toxic, is really necessary. Although not the topic of this discussion, the same question may apply among younger adults.
Another issue that often arises is how many cycles of highdose cytarabine are needed as optimal post-remission therapy. The published data range from one to four or five cycles, often an impossible target among older adults. However, there have been no prospective evaluations of the optimal number of cycles of high-dose cytarabine needed for consolidation therapy at any age and thus, the number of cycles of high-dose cytarabine required in standard post-remission therapy is something that is presently unknown and needs to be studied. A current prospective study is being conducted by ECOG (E7996) which randomizes older adults to one or more courses of high-dose cytarabine.
What is the role of maintenance therapy?
The entire issue of maintenance therapy appears to be underrated and does not give proper consideration to the existing data, especially in the context of an older adult population in whom it may be difficult to administer standard intensive postremission therapy. A study by the ECOG in 1983 used standard induction therapy and was followed by post-induction randomization to allogeneic bone marrow transplantation if a donor was available; if not, patients were randomized to receive no therapy, maintenance therapy or consolidation therapy. In this study, maintenance therapy consisted of 6-thioguanine, 40 mg/m 2 for 4 days, followed by cytosine arabinoside on day 5 and this was repeated weekly for 2 years. 28 A part of this study was closed early because the observation arm was significantly worse than those patients who received maintenance therapy. This was the first prospective study that demonstrated the need for some form of post-remission therLeukemia apy and, importantly, showed that maintenance therapy was definitely effective in AML. It did not appear to be as effective as intensive consolidation, but it nevertheless was definitely effective. Similar data from the German Acute Leukemia Group 29 described patients who were randomized following consolidation therapy to receive maintenance therapy or not receive maintenance therapy. The disease-free survival at 3 years was 30% for patients who received maintenance therapy vs 17% on the observation arm (P = 0.003). Thus, maintenance therapy in AML is clearly effective. It is doubtful whether it has a role in younger adults who are able to tolerate intensive post-remission therapy but it is likely to have a role among older adults. This is clearly under-utilized and needs to be more rigorously and prospectively investigated.
What is the role of immunotherapy?
One of the areas of greatest promise, and one that often minimizes the stresses of myeloablation is immunotherapy. It is likely that the greatest progress, especially for older adults, is going to come from this area although one need not belittle its potential effect also for younger adults.
Monoclonal antibodies
Initial work on the development of monoclonal antibodies had led to the hopes that this would lead directly to an effective anti-tumor therapy. For two decades the clinical studies have been mostly disappointing. However, refinements to the initial technology and recent developments have put monoclonal antibody-based immunotherapy back in the forefront of some of the most exciting innovations in the therapy of AML. Current interest has focused on the antibody conjugate, calicheamicin gamma, which is a novel, very toxic drug moiety conjugated to anti-CD33 antibody. 30 Because the CD33 antigenic expression is almost exclusively limited to the hematopoietic system, and occurs mostly on AML cells but not in normal hematopoietic elements, this has become a very attractive conjugate with the potential to inhibit growth of AML cell lines and growth of leukemic colony-forming cells. 31 This conjugate, now known as CMA-676, is the drug antibody conjugate under greatest focus. Recent data 32 reported on 23 relapsed AML patients among whom 43% responded; three went into complete remission and seven also went into remission except that they did not have the required 100 000/l platelets that is usually mandated for a definition of the complete response. However, they met all the other criteria for complete remission and certainly established the efficacy of this single agent in the therapy of relapsed AML such that clinical trials in de novo AML will shortly be undertaken. Clearly, this represents one of the most novel and potentially exciting approaches to the therapy of AML and one may expect to hear much more about the CMA-676 conjugate.
IL-2
IL-2 has been around for a long time and has almost become accepted as an important immunomodulator in AML post therapy. 33 Rather surprisingly, despite the wealth of phase I and phase II information, there has never been a convincing phase III study that has shown its effect post remission in AML. Several such cooperative group studies have been launched but have closed early due to inadequate patient accrual. A current ongoing phase III study conducted by the CALGB (9720) is prospectively evaluating IL-2 post remission in patients over 60 years. It is hoped that this study will meet its accrual goal and will give a definitive answer as to the precise role of IL-2 in this setting.
An interesting international effort is underway evaluating the role of IL-2 and histamine. The rationale for this combination is based on the fact that IL-2 is generally thought to act by activation of NK cells as well as cytotoxic lymphocytes. It is also known that monocytes inhibit IL-2-induced activation of NK cells and of lymphocytes. The inhibition of cytotoxicity by monocytes is thought to be due to the monocyte-derived reactive oxygen metabolites. Histamine is known to inhibit production of these reactive oxygen metabolites and therefore is a candidate for an ongoing prospective phase III study, especially after promising preliminary phase I/II data that were published 2 years ago. 34 
Flt3 ligand
One of the most intriguing and interesting immunotherapeutic agents that have been developed in the past few years is Flt3 ligand (Flt3L) and this too has enormous potential for the therapy of AML. [35] [36] [37] [38] Flt3L is a growth factor with structural similarity to stem cell factor and CSF1. Flt3L stimulates human and mouse hematopoietic progenitor cells to proliferate and it stimulates the generation of human and mouse dentritic cells. One of the problems in the past has been the very small number of dendritic cells that was available for any demonstrable clinical efficacy.
Flt3L-generated dendritic cells have been shown to be imunophenotypically negative for CD1a, CD3, CD14, CD19, CD56, CD34 and positive for CD33, CD11c, CD86 and HLA-DR. They have characteristic veiled and dendritic processes and they stimulate the mixed lymphocyte response. A fundamental property of Flt3L in tumor therapy has been its remarkable ability to expand the number of functioning dendritic cells and increase the uptake and presentation of tumor-associated antigens. In addition, it stimulates tumor-specific cytotoxic lymphocytes. Importantly, Flt3-generated dendritic cells are as functionally competent as freshly isolated dendritic cells from untreated mice. Flt3 is also a very safe molecule, as shown by investigations in healthy human volunteers. Table 6 schematically outlines a phase III study that is under development by the Eastern Cooperative Oncology Group which essentially will prospectively look at patients in remission and compare them giving six cycles of Flt3L vs observation only and see what effect this has on increasing or delaying disease progression. Year in which study was first presented in abstract (not always year of publication).
What is the role of MDR modulation?
Ongoing studies are in progress on several potential multidrug resistance (MDR) modulators. 40 It is fair to say, however, that the predominant current focus is on PSC833 which is at present the mostly widely studied MDR modulator. It is a nonimmunosuppressive and a non-nephrotoxic cyclosporine analog. It is two-to 10-fold more potent than cyclosporine in modulating MDR and at the present time there are major ongoing phase III studies both in de novo (CALGB 9720) and in advanced AML (ECOG 2995). Although this is one of the areas under most intensive focus at the present time, caution here is in order as most of the preliminary reported datawhile confirming the in vitro MDR modulation -have not demonstrated striking clinical evidence of its efficacy. 41, 42 The importance of the current studies by the CALGB and ECOG is that pharmacokenetic considerations have been factored into the randomization such that patients who received PSC833 receive significantly lower doses of anthracyclines and VP-16 -the primary target of MDR modulation. The problem with analyzing several ongoing, and recently published studies 43 is the difficulty in interpreting the effect of an MDR 
What is the role of cytokines in AML?
It is surprising that despite 14 major controlled trial of growth factors after induction therapy for AML (Table 7) , controversies still abound. 21, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] Virtually all the studies, with the exception of one very small report, have shown a significant reduction in the days to neutrophil recovery of 500/l to 1000/l and some of them have documented reduced morbidity. Data now exist on close to 3500 patients followed in these 14 well-controlled clinical trials. It is unfortunate that lingering doubts remain, in publications or in clinical practice, regarding the safety of cytokines in AML. However, the preponderance of the data have convincingly shown that cytokines are safe when used in induction or consolidation therapy. The problem in assessing outcome is that one is looking for major differences in survival or in response rate of AML, and failing to demonstrate that in many studies, seems to be a reason for hesitation in the use of cytokines. It is important to think of cytokines as supportive care measures like, for example, central venous catheters which are probably not cost-effective; increase rather than decrease infection and yet there are very few individuals or centers who do not use them, owing to the benefit for the overall well being of the patients. Cytokines are similarly an important supportive care measure ¼ Phase III studies of experimental approaches (eg PSC 833) are to be strongly encouraged ¼ Low dose Ara-C (or similar) should only be given to those with significant co-morbidities -probably at doses that are not myeloablative.
¼ At least one course of high-dose Ara-C -at 1.5 g/m 2 every 12 h for 6-12 doses -should be offered as consolidation ¼ Because most will relapse, patients should probably receive some form of maintenance therapy or enter some form of easily-tolerated experimental protocols employing: Immunotherapy monoclonal antibodies IL-2 Flt3 ligand vaccines Biologically active agents angiogenesis inhibitors molecules impacting on signal transduction bryostatin ¼ Cytokines -GM-CSF or G-CSF are safe, well tolerated and significantly shorten the period of neutropenia Should be routinely given to older adults after induction therapy -as a supportive care measure Should, similarly, be given post any intensive consolidation therapy At the present time, should not be used as priming agents outside of clinical trials 56, 66, 67 Leukemia that significantly reduce the period of neutropenia. Studies of cost-effectiveness, using yeast-derived GM-CSF or G-CSF have also shown the benefit of growth factors. [59] [60] [61] [62] [63] An exception has been a cost-effectiveness study using the more toxic E. coli-derived GM-CSF in AML. 64 Thus, cytokines should be routinely used, following induction therapy for acute leukemia, at least in those patients with anticipated high risk for therapy-related morbidity.
Summary
The overall strategy for the treatment of older adults is summarized in Table 8 . Soon after the birth of effective chemotherapy for acute leukemia, the perspective for all patients was summarized as follows: 'With all humility it may be claimed that there are, at least, grounds for hope and encouragement in this recently acquired ability occasionally to halt for a while the formerly unrelenting malignant process known as acute leukemia'. 65 In reviewing the overall survival data for older adults one may feel that we are at a similar juncture in assessing the outcome for this particular population. It is hoped that some of the potential advances may provide greater hope and improved results over the next decade.
